SCHEMBL200967

SCHEMBL200967

CC(C)(C)OC(=O)N1CC=CC1C(=O)NOCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 5/20 0.41
STS P08842 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PARP1 P09874 1/20 0.40
KLK7 P49862 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39
SYK P43405 1/20 0.39
HTRA1 Q92743 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200968 1.00 GHSR (0.41) GHSRSTSMEN1KMT2APARP1
SCHEMBL201235 0.85 NPC1 (0.46) NPC1RAB9ASMN1; SMN2PSEN1PSEN2
SCHEMBL18562186 0.83 PSEN1 (0.45) MEN1KMT2APARP1KLK7PSEN1
SCHEMBL8280176 0.83 PSEN1 (0.45) MEN1KMT2APARP1KLK7PSEN1
SCHEMBL3546934 0.80 MEN1 (0.50) GHSRSTSMEN1KMT2AKLK7
SCHEMBL3546930 0.80 MEN1 (0.50) GHSRSTSMEN1KMT2AKLK7
SCHEMBL3547348 0.78 KMT2A (0.58) MEN1KMT2AKLK7NPC1RAB9A
SCHEMBL3547345 0.78 KMT2A (0.58) MEN1KMT2AKLK7NPC1RAB9A
SCHEMBL203307 0.77 GHSR (0.41) GHSRSTSMEN1KMT2APARP1
SCHEMBL201382 0.77 STS (0.43) GHSRSTSMEN1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 GHSR 1457/4885STS 624/4885MEN1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.